Skip to main content


Generic name: topiramate
Dosage form: oral solution
Drug class: Carbonic anhydrase inhibitor anticonvulsants

Medically reviewed by Judith Stewart, BPharm. Last updated on Oct 30, 2023.

What is Eprontia?

Eprontia is a prescription medicine used:

Important information

Eprontia may cause eye problems. Serious eye problems include:

Eprontia may cause decreased sweating and increased body temperature (fever). People, especially children, should be watched for signs of decreased sweating and fever, especially in hot temperatures. Some people may need to be hospitalized for this condition. If a high fever, a fever that does not go away, or decreased sweating develops, call your healthcare provider right away.

Eprontia can increase the level of acid in your blood (metabolic acidosis). If left untreated, metabolic acidosis can cause brittle or soft bones (osteoporosis, osteomalacia, osteopenia), kidney stones, can slow the rate of growth in children, and may possibly harm your baby if you are pregnant.
Metabolic acidosis can happen with or without symptoms. Sometimes people with metabolic acidosis will:

Your healthcare provider should do a blood test to measure the level of acid in your blood before and during your treatment with Eprontia. If you are pregnant, you should talk to your healthcare provider about whether you have metabolic acidosis.
Like other antiepileptic drugs, Eprontia may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.
Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:

Do not stop Eprontia without first talking to a healthcare provider.

How can I watch for early symptoms of suicidal thoughts and actions?

Eprontia can harm your unborn baby.

Pregnancy Registry: If you become pregnant while taking Eprontia, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of Eprontia and other antiepileptic drugs during pregnancy.

Before taking Eprontia

Before taking Eprontia, tell your healthcare provider about all of your medical conditions, including if you:

What other drugs will affect Eprontia?

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Eprontia and other medicines may affect each other causing side effects.

Especially tell your healthcare provider if you take:

Ask your healthcare provider if you are not sure if your medicine is listed above.

Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine. Do not start a new medicine without talking with your healthcare provider.

How should I take Eprontia?

Your healthcare provider may do blood tests while you take Eprontia.

Dosing information

Usual dose for Epilepsy Monotherapy in Adults and Pediatric Patients (10 years of age and older)

The recommended dose for Eprontia monotherapy in adults and pediatric patients 10 years of age and older is 400 mg/day in two divided doses. The dose should be achieved by titration according to the following schedule:

  Morning Dose Evening Dose
Week 1 25 mg 25 mg
Week 2 50 mg 50 mg
Week 3 75 mg 75 mg
Week 4 100 mg 100 mg
Week 5 150 mg 150 mg
Week 6 200 mg 200 mg

Usual dose for Epilepsy Monotherapy in Pediatric Patients (2 to 9 Years of Age)

Dosing in patients 2 to 9 years of age is based on weight. During the titration period, the initial dose of Eprontia is 25 mg/day nightly for the first week. Based upon tolerability, the dosage can be increased to 50 mg/day (25 mg twice daily) in the second week. Dosage can be increased by 25–50 mg/day each subsequent week as tolerated. Titration to the minimum maintenance dose should be attempted over 5–7 weeks of the total titration period. Based upon tolerability and clinical response, additional titration to a higher dose (up to the maximum maintenance dose) can be attempted at 25–50 mg/day weekly increments. The total daily dose should not exceed the maximum maintenance dose for each range of body weight.

Weight (kg) Total Daily Dose (mg/day)*
Minimum Maintenance Dose
Total Daily Dose (mg/day)*
Maximum Maintenance Dose
Up to 11 150 250
12-22 200 300
23-31 200 350
32-38 250 350
Greater than 38 250 400

* Administered in two equally divided doses

Usual dose for Epilepsy Adjunctive Therapy in Adults (17 Years of Age and Older)

The recommended total daily dose of Eprontia as adjunctive therapy in adults with partial onset seizures or Lennox-Gastaut Syndrome is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-clonic seizures. Eprontia should be initiated at 25 to 50 mg/day, followed by titration to an effective dose in increments of 25 to 50 mg/day every week. Titrating in increments of 25 mg/day every week may delay the time to reach an effective dose. Doses above 400 mg/day have not been shown to improve responses in adults with partial-onset seizures.

Usual dose for Epilepsy Adjunctive Therapy in Pediatric Patients (2 to 16 Years of Age)

The recommended total daily dose of Eprontia as adjunctive therapy for pediatric patients 2 to 16 years of age with partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome is approximately 5 to 9 mg/kg/day in two divided doses. Titration should begin at 25 mg/day (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome. The total daily dose should not exceed 400 mg/day.

Usual dose for Preventive Treatment of Migraine

The recommended total daily dose of Eprontia as treatment for patients 12 years of age and older for the preventive treatment of migraine is 100 mg/day administered in two divided doses. The recommended titration rate for Eprontia for the preventive treatment of migraine is as follows:

  Morning Dose Evening Dose
Week 1 None 25 mg
Week 2 25 mg 25 mg
Week 3 25 mg 50 mg
Week 4 50 mg 50 mg

Dose and titration rate should be guided by clinical outcome. If required, longer intervals between dose adjustments can be used.

What should I avoid while taking Eprontia?

Eprontia side effects

Eprontia may cause serious side effects including:

See Important information

Call your healthcare provider right away if you have any of the symptoms above.

The most common side effects include:

Tell your healthcare provider about any side effect that bothers you or that does not go away. These are not all the possible side effects of Eprontia. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Azurity Pharmaceuticals, Inc. at 1-855-379-0383.

How should I store Eprontia?

Keep all medicines out of the reach of children and pets.

General information about the safe and effective use of Eprontia.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use this medicine for a condition for which it was not prescribed. Do not give it to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information that is written for health professionals.

What are the ingredients in Eprontia?

Active ingredient: Topiramate
Inactive ingredients: glycerin, methylparaben, mixed berry flavor, polyethylene glycol, propylparaben, and sucralose.

Popular FAQ

Yes, topiramate (Topamax) has been shown to cause weight loss when used for both seizure control and migraine prevention. Topiramate by itself is not specifically approved by the FDA for weight loss, but is used in an "off-label" fashion for this condition. Qsymia, an extended-release medicine that contains phentermine and topiramate, is FDA approved for weight loss, along with diet and exercise. Continue reading

Yes, topiramate has been shown to cause hair loss in studies, but it is not a common side effect. Hair loss (also called alopecia) has been reported in 1% to 4% of children ages 6 to 16 years of age, and in 3% to 4% of patients older than 16 years of age. Higher daily doses (400 mg/day) of topiramate were associated with greater rates of hair loss than lower doses (50 mg/day) in both age groups. Continue reading

You can usually stay on Topamax (topiramate) to help prevent your migraine headaches as long as the treatment is needed and remains safe for you. You and your doctor will decide how long you stay on treatment. This will be based on how well it is working for you and any side effects you may experience. Continue reading

It may take 8 to 12 weeks for you to see the full effect of Topamax on your migraine headaches. In clinical studies, some people had fewer headaches after 4 weeks of treatment. In the treatment of epilepsy, Topamax is also started slowly and the dose is increased over a 6-week period. Continue reading

Topamax stays in your system for approximately 4 to 5 days after the last dose, but this may vary depending on personal factors, such as your age, weight, dosage, and what other medications you currently take. This estimate is based on the half-life of Topamax which is about 21 hours and experts agree that it takes up to 5 half-lives for a drug without active metabolites to be completely removed from the body. A drug’s half-life is the time it takes for 50% of that drug to be removed from the body. Topamax does have some metabolites, but these are not considered active and only make up about 5% of an administered dose. This means it takes 84 to 105 hours for Topamax to leave your body. Continue reading

Trokendi (topiramate) XR can lead to weight loss when used for prevention of migraine headaches or seizures, but it is not approved as a weight loss medicine. Loss of appetite and other digestive issues, which may contribute to weight loss, have been reported in topiramate studies. Continue reading

Topamax and Trokendi XR and are both approved by the FDA for seizure control in certain forms of epilepsy and for migraine headache prevention, but there are differences between these drugs, including approved ages for use, dosage forms, and dosing schedules. Continue reading

Topiramate is a prescription medication, taken alone or with other medicines to control certain types of seizures due to epilepsy. It is also used for the prevention of migraine headaches. Continue reading

More FAQ

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.